Ablynx is a biopharmaceutical company specializing in the discovery and development of Nanobodies®, a novel class of single-domain antibody fragments derived from camelid heavy-chain only antibodies. These small, robust building blocks offer unique properties including high specificity, stability and the potential for improved tissue penetration. Ablynx’s research efforts are primarily focused on creating targeted therapies for a range of serious and life-threatening conditions, including inflammation, thrombosis, oncology and rare genetic disorders.
Central to Ablynx’s strategy is its proprietary Nanobody platform, which drives both its internal development pipeline and collaborative partnerships with leading pharmaceutical companies. Over the years, the company has established strategic alliances to leverage its technology in multiple therapeutic areas, enabling access to additional research resources and accelerating clinical progress. Key candidates have advanced through various stages of clinical trials, showcasing the versatility of the Nanobody approach across different disease mechanisms.
Founded in 2001 and headquartered in Ghent, Belgium, Ablynx has expanded its global footprint with research facilities and offices in Europe and the United States. The company’s international network supports discovery, preclinical development and early-stage clinical activities, underpinned by state-of-the-art laboratories and collaborative research environments. In 2018, Ablynx became part of a larger international pharmaceutical organization, reinforcing its capacity to scale up manufacturing and global commercialization efforts.
Ablynx’s leadership team combines deep expertise in antibody engineering, translational medicine and business development. Guided by seasoned executives and a board with extensive industry experience, the company continues to advance its pipeline and explore new indications for its Nanobody technology. With its integrated research model and strategic collaborations, Ablynx remains committed to bringing innovative therapies to patients worldwide.
AI Generated. May Contain Errors.
